NCT01381692 - Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2011

Primary Completion Date

December 8, 2014

Study Completion Date

September 1, 2021

Conditions

Recurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRefractory Non-Hodgkin LymphomaRefractory Small Lymphocytic Lymphoma

Interventions

DRUG

Bortezomib

Given IV or SC

DRUG

Dexamethasone

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Rituximab

Given IV

DRUG

Temsirolimus

Given IV

Trial Locations (11)

17822

Geisinger Medical Center, Danville

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

53226

Medical College of Wisconsin, Milwaukee

54449

Marshfield Medical Center-Marshfield, Marshfield

54548

Marshfield Clinic-Minocqua Center, Minocqua

54601

Gundersen Lutheran Medical Center, La Crosse

55905

Mayo Clinic in Rochester, Rochester

80218

Presbyterian - Saint Lukes Medical Center - Health One, Denver

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH